Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Slides:

Advertisements

Similar presentations

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165:

Advertisements

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:

Weng TC, et al. J Clin Pharm Ther 2010;35:

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.

Philip J. Barter, et al. Circulation 2011;124:

Flow of Participants Through the Trial David J. A. Jenkin et al. JAMA 2008;300:

Design of a multicohort evaluation of statin adherence after the start of 2 cost-sharing policies Sebastian Schneeweiss, et al. Circulation 2007;115:

Characteristics of new users of statins in the period 1991–2004 in the PHARMO population F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159.

Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:

Demographic Characteristics of the Study Population - Part I Jenny N.Poynter et al N Engl J Med 2005;352:

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

David J. Graham et al. JAMA, 2004; 292: 2585 Description of Inception Cohorts for Patients Using Statin and Fibrate Drug Therapy.

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:

Shalev V, et al. Arch Intern Med 2009; 169:

Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

Multivariate associations* between selected covariates and statin use Jawahar L. Mehta, et al. Am J Cardiol 2006;98:923–928.

Definition of measurements and patients Michael J. Murphy, et al. Br J Clin Pharmacol 2008;65:

Baseline Mean Daily Servings of Coffee and Other Beverages and of Caffeine in Women in the Iowa Women’s Health Study, 1986* *Data are given as.

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Flowchart of participants

Baseline Characteristics of the Patients Part I

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

Design of a multicohort evaluation of statin adherence after the start of 2 cost-sharing policies Sebastian Schneeweiss, et al. Circulation 2007;115:

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

CHOICE: Relative risk of death on peritoneal dialysis vs hemodialysis

Adjusted relative mortality risk

Jun M, et al. Lancet 2010 Epub May 10

Description of studies for pooled analyses

Fung TT, et al. Circulation 2009;119:

Hajer GR et al. Atherosclerosis 2009;202:216-24

NAFLD (nonalcoholic fatty liver disease), CVD, and type 2 diabetes: Details of the study design Targher G et al. Diabetes Care 2007;30:

Classification of statins/dosages according to the attainable

Baseline Characteristics of 400 Women Who Subsequently Developed Incident Hypertension (Case Subjects) and 400 Women Who Remained Free of Hypertension.

Baseline Characteristics

Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%

Enrollment and Outcomes

Flow of Patients Through the Trial

Temporal changes in population rates of cardiac services, demographics, and AMI prevalence (relative to 1992) David A. Alter, et al, Circulation 2006;113;

Number of Monthly Ezetimibe Prescriptions in the United States and Canada from 2002 to 2006 Data are from the National Prescription Audit of IMS Health.

Study Participant Flow

A.V. Khera et al. N Engl J Med 2011;364:127-35

Baseline Characteristics of the Study Participants

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Jeffrey S. Berger, et al. Circ Cardiovasc Qual Outcomes 2009;2:78-87

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Baseline Characteristics of Study Populations

Characteristics of Participants in the Nurses Health Study According to Alcohol Intake Meir J.Stampfer et al N Engl J Med 2005;352:

Perreault S, et al. Eur J Clin Pharmacol 2009 Jun 16 [Epub]

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.

Baseline Lipid Parameters and Characteristics Among 3110 Men According to Quintiles of Total Cholesterol Ruben O. Halperin et al, Hypertension 2006;47;45-50.

Baseline characteristics of older women (NHS I), younger women (NHS II), and men (HPFS) with a history of hypertension according to thiazide use Eric N.

Baseline Characteristics by hs-CRP

Baseline characteristics of the 1,842 men without coronary heart disease and the 230 men with a first coronary heart disease event during the 13-year.

Flow chart of search strategy

A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Davide Capodanno et al. JCIN 2009;2:

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Flow of study participants

Trajectories over the 9 years of follow-up of HbA1c in all participants (n = 4,080 at baseline), stratified by the presence of a family history of diabetes,

ORs of receiving metformin for outcome measures, including age, number of comorbidities, provider age, A1C level, history of CHF, and use of medications,

A: Probability of SICH by baseline glucose level.

Survival RR enhancement according to the specific protocol in treated mice. Survival RR enhancement according to the specific protocol in treated mice.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Baseline characteristics of study participants according to education and two subgroups Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Number of statin users 2004–2006 among participants in population-based studies 2000–2002, who reported never use of statins at baseline Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Adjusted relative risk (RR) of starting statin treatment among participants in population-based studies 2000-2002, who reported never use of statins at baseline Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Probability of statin treatment in 2004-2006 according to total cholesterol at baseline in 2000-2002 and educational level Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Number of statin prescriptions dispensed in the period 2004-2006 among study participants (n=1842), by level of education and subgroup Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62